Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.47 |
| ▸ | CTSL | P07711 | 9/20 | 0.47 |
| ▸ | CTSB | P07858 | 7/20 | 0.47 |
| ▸ | CTSS | P25774 | 7/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4954962 | 0.92 | CTSK (0.41) | CTSKCTSLCTSBCTSSALOX5 | |
| SCHEMBL2156492 | 0.91 | CTSK (0.48) | CTSKCTSLCTSBCTSSALOX5 | |
| SCHEMBL2155441 | 0.89 | CTSL (0.44) | CTSKCTSLCTSBCTSS | |
| SCHEMBL15855772 | 0.89 | CTSL (0.44) | CTSKCTSLCTSBCTSS | |
| SCHEMBL2155832 | 0.89 | CTSL (0.46) | CTSKCTSLCTSBCTSS | |
| SCHEMBL5744221 | 0.87 | CTSK (0.39) | CTSKCTSLCTSBCTSS | |
| SCHEMBL2157013 | 0.87 | CTSL (0.48) | CTSKCTSLCTSBCTSS | |
| SCHEMBL2155905 | 0.87 | CTSL (0.41) | CTSKCTSLCTSBCTSS | |
| SCHEMBL2155593 | 0.87 | CTSL (0.37) | CTSKCTSLCTSBCTSS | |
| SCHEMBL2156379 | 0.87 | CTSL (0.37) | CTSKCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973037-B2 | Cathepsin cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20080188529-A1 | N1-(cyanomethyl)-N2-(2,2,2-trifluoro-1-phenylethyl)-L-leucinamide; antiarthritic agent; osteoporosis and other bone loss disorders | MERCK CANADA INC. (CA) | 2008-08-07 | — | — | US | disclosed |
| EP-1482924-A4 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2006-03-08 | — | — | EP | disclosed |
| EP-1482924-A2 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003075836-A2 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188529-A1 | N1-(cyanomethyl)-N2-(2,2,2-trifluoro-1-phenylethyl)-L-leucinamide; antiarthritic agent; osteoporosis and other bone loss disorders | CTSE, CTSL, CTSK | CTSK 3/4885CTSL 2/4885CTSB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.